tbuckley/cabot-search huggingface dataset:
NCOG-09. STRUCTURED EVALUATION OF PATIENTS WITH LOW-GRADE GLIOMA BY AN OCCUPATIONAL THERAPIST - IS OUR CLINICAL EXAMINATION ENOUGH?
Authors: Christian Freyschlag, Johannes Kerschbaumer, Daniel Pinggera, Claudius Thomé, Gabriele Bacher
Journal: Neuro-Oncology (2016)

For optimal treatment of patients with diffuse low-grade gliomas (dLGG), preservation of neurological function is mandatory when offering a surgical resection, given that the predominantly young patients have to be able to return to work. To determine whether a structured evaluation by an occupational therapist can reveal deficits that might be overseen in routine clinical examination of patients with a surgically treated dLGG. Fifteen patients with radiographic suspected low-grade gliomas have been examined objectively by an occupational therapist at three stages: pre-, postoperatively and after three months. Evaluation consisted of simple forcemeter-testing and mirroring-tasks, followed by stereognostic evaluation and a 9-hole PEG-test. Finally patients underwent an ARA-test (Action research arm test). Descriptive and statistical analysis of the results was performed. Thirteen patients (86,6%) showed no postoperative motor deficit, one suffered akinesia due to SMA involvement and one demonstrated a transient hemiparesis with manifestation on the first postoperative day. Patients with eloquent dLGGs, involving speech (n=8, 53,3%), exhibited different transient speech disturbances according to the localization of the lesion. Structured testing revealed a postoperative worsening of movement mirroring (upper extremity) and finger discrimination (sensory) in 10 of 15 patients (66%). Stereognostic discrimination of objects and forcemeter evaluation of the upper extremity was significantly decreased in all patients (p=0.06) for the affected hemisphere even though motor deficits were absent in most patients. The deficits recovered within the first 3 months. The ARA test also showed significant deterioration (p= 0,006 (pinch) and p=0.016 (gross movement) in all patients postoperatively, with a complete restitution at 3 months postoperatively. Routine clinical examination and neuropsychological evaluation fails to detect mild deficits in sensory function, reactivity and apraxia. Nonetheless, there is a lack of robust data and ongoing research should elaborate the role of a structured evaluation of an occupational therapist.
FRI0126 Aiming for remission according to any of the rheumatoid arthritis disease activity indices is more important for physical function than the actual choice of index: a longitudinal analysis in a clinical practice setting (meteor cohort)
Authors: PD Carvalho, R Ferreira, R Landewé, D Vega-Morales, K Salomon-Escoto, DJ Veale, J da Silva, PM Machado
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> The association between remission and disability in patients with rheumatoid arthritis (RA) has been established mainly in clinical trial cohorts and not in “real-life” patients. Moreover, only a limited number of remission definitions have been tested. <h3>Objectives</h3> To compare the association between different remission criteria and physical function in patients with RA followed in clinical practice. <h3>Methods</h3> Longitudinal data from the METEOR database were used. Fifteen definitions of remission were tested: ACR-EULAR boolean-based; Simplified Disease Activity Index (SDAI); Clinical Disease Activity Index (CDAI); Disease Activity Score (DAS) and 28-joint count DAS (DAS28), both with ESR/CRP, with 3/4 variables (3v/4v), and various cut-offs tested. Disability was measured by the Health Assessment Questionnaire (HAQ) and HAQ≤0.5 was defined as a good outcome. Associations were investigated using generalised estimating equations (GEE), using HAQ≤0.5 as dependent variable and the various remission criteria as independent variables. Potential confounding factors (age, body mass index, gender, rheumatoid factor positivity, erosions and biologic treatment) were also tested. Sensitivity analyses were performed using first visits only and using patients with no missing data for all definitions of remission. <h3>Results</h3> Data from 32,915 patients and 157,899 visits were available. The most stringent definition of remission (table 1) was the ACR-EULAR boolean definition (4.5%). The proportion of patients with HAQ≤0.5 among patients in remission was higher for the most stringent definitions. However, this also meant that, for the most stringent criteria, many patients in non-remission had HAQ≤0.5. The strongest degree of association between remission and HAQ≤0.5 was observed for the SDAI. However, only minor differences were noted between definitions (table 1). Sensitivity analyses yield similar results (not shown). <h3>Conclusions</h3> The various remission definitions confirmed their validity in terms of physical function in a large international clinical practice setting. However, many patients in non-remission will still have good functional status and being in clinical remission does not equate to having HAQ≤0.5. A multidimensional approach should be taken to help patients achieve this functional goal. Achievement of remission according to any of the indices is more important than the use of a specific index. <h3>Disclosure of Interest</h3> None declared
A phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC)
Authors: D. Rischin, M.G. Fury, I. Lowy, E. Stankevich, S. Li, H. Han, S.V. Porceddu
Journal: Annals of Oncology (2019)
An Elderly Bias, Nocturia, and Adverse Effects of Sedative-Hypnotic Medication
Authors: Seo-Eun Cho, Seung-Gul Kang, Kyoung-Sae Na
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue
An Exploration of Barriers, Facilitators, and Suggestions for Improving Electronic Health Record Inbox-Related Usability
Authors: Daniel R. Murphy, Traber D. Giardina, Tyler Satterly, Dean F. Sittig, Hardeep Singh
Journal: JAMA Network Open (2019)

<h3>Importance</h3> Managing messages in the electronic health record (EHR) inbox consumes substantial amounts of physician time. Certain factors associated with inbox management, such as poor usability and excessive and unnecessary inbox messages, have been associated with physician burnout. Additionally, inbox design, usability, and workflows are associated with physicians' situational awareness (ie, perception, comprehension, and projection of clinical status) and efficiency of processing EHR inbox messages. Understanding factors associated with inbox usability could improve future EHR inbox designs and workflows, thus reducing risk of burnout while improving patient safety. <h3>Objective</h3> To determine barriers, facilitators, and suggestions associated with EHR inbox-related usability. <h3>Design, Setting, and Participants</h3> This qualitative study included cognitive walkthroughs of EHR inbox management with 25 physicians (17 primary care physicians and 8 specialists) at 6 large health care organizations using 4 different EHR systems between May 6, 2015, and September 19, 2016. While processing EHR inbox messages, participants identified facilitators and barriers associated with EHR inbox situational awareness and processing efficiency and potential interventions to address such barriers. A qualitative analysis was performed on transcribed recordings using an inductive thematic approach with an 8-dimension sociotechnical model as a theoretical lens from May 6, 2015, to August 15, 2019. <h3>Results</h3> The cognitive walkthroughs identified 60 barriers, 32 facilitators, and 28 suggestions for improving the EHR inbox. Emergent data fit within 5 major themes: message processing complexity, inbox interface design, cognitive load, team communication, and inbox message content. Within these themes, similar barriers were identified across sites, such as poor usability due the high numbers of clicks needed to accomplish actions. In certain instances, an identified facilitator at one site provided the exact solution needed to address a barrier identified at another site. <h3>Conclusions and Relevance</h3> This qualitative study found that usability of the EHR inbox is often suboptimal and variable across sites, suggesting lack of shared best practices related to information management. Implementation of optimized design features and workflows will require EHR developers and health care organizations to collectively share this responsibility. Development of regional or national consortia to support collaborative sharing and implementation of EHR system best practices across EHR developers and health care organizations could also improve safety and efficiency and reduce physician burnout.
Pharmacokinetic/ pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study
Authors: M. Maio, S.L. Groenland, T. Bauer, D. Rischin, I. Gardeazabal, V. Moreno, J.M. Trigo Perez, M. Chisamore, J. Sadik Shaik, F. Rigat, C. Ellis, H. Chen, R. Gagnon, S. Scherer, D. Turner, S. Yadavilli, M. Ballas, A. Hoos, E. Angevin
Journal: Annals of Oncology (2019)
MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer (ABC)
Authors: S.M. Tolaney, A.M. Wardley, S. Zambelli, J. Hilton, T. Troso-Sandoval, F. Ricci, S.-A. Im, S.-B. Kim, S.R.D. Johnston, A. Chan, S. Goel, K. Catron, Z. Yang, C. Gainford, F. André
Journal: Annals of Oncology (2019)
Identification of ultralow risk breast cancer patients (probable overdiagnosis)
Authors: S Gamez Casado, M Bernal Gómez, A Campini Bermejo, L Rodriguez Perez, A. Quilez, J Calvete Candenas, G Martínez Bernal, E Benítez Rodríguez, J.M. Baena-Canada
Journal: Annals of Oncology (2019)
FOLFIRINOX in locally advanced (LA) and borderline resectable (BR) pancreatic adenocarcinoma: Update of the AGEO cohort
Authors: E. Auclin, L. Marthey, L. Mas, E. Francois, A. Sa Cunha, J.-B. Bachet, D. Tougeron, A. Vienot, T. Lecomte, V. Hautefeuille, J. Forestier, M. Collins, R. Abdallah, R. Coriat, A.-L. Pointet, F. Leroy, F. Ksontini, N. Williet, J. Taieb
Journal: Annals of Oncology (2019)
Circulating uromodulin inhibits systemic oxidative stress by inactivating the TRPM2 channel
Authors: Kaice A. LaFavers, Etienne Macedo, Pranav S. Garimella, Camila Lima, Shehnaz Khan, Jered Myslinski, Jeanette McClintick, Frank A. Witzmann, Seth Winfree, Carrie L. Phillips, Takashi Hato, Pierre C. Dagher, Xue-Ru Wu, Tarek M. El-Achkar, Radmila Micanovic
Journal: Science Translational Medicine (2019)

Uromodulin inhibits systemic oxidative stress via TRPM2.
Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers
Authors: S.I. Labidi-Galy, T. deLa Motte Rouge, O. Derbel, A. Wolfer, E. Kalbacher, T. Olivier, J.-D. Combes, K. Hu-Heimgartner, O. Tredan, H. Guevara, V. Heinzelmann-Schwarz, M. Fehr, V. de Castelbajac, P. Vaflard, L. Crivelli, V. Bonadona, V. Viassolo, F. Bazan, M. Rodrigues, I.L. Ray-Coquard
Journal: Annals of Oncology (2019)
Pemetrexed is more effective in patients with nonsquamous non-small cell lung cancer (NSCLC) histology: an analysis of three large, randomized, phase III trials
Authors: Giorgio Scagliotti, Thomas Brodowicz, Frances Shepherd, Christoph Zielinski, Johan Vansteenkiste, Christian Manegold, Lorinda Simms, Frank Fossella, Katherine Sugarman, Chandra Belani
Journal: Journal of Thoracic Oncology (2009)
PRECYCLE: Impact of CANKADO-based eHealth-support on quality of life in metastatic breast cancer patients treated with palbociclib and endocrine therapy
Authors: T. Degenhardt, P.A. Fasching, D. Lüftner, V. Müller, C. Thomssen, C. Schem, I. Witzel, T. Decker, H. Tesch, S. Kuemmel, C. Uleer, R. Wuerstlein, C. Riese, T. Schinköthe, R.E. Kates, J. Schumacher, N. Harbeck, M. Schmidt
Journal: Annals of Oncology (2019)
Phase II study of the combination of cisplatin + temozolomide in malignant glial tumours in children and adolescents at diagnosis or in relapse (cistem2/nct00147160)
Authors: J. Grill, S. Lowis, D. Frappaz, A. Michalski, S. Picton, A. Jouvet, K. Robson, T. Jaspan, D. Couanet, M. Le Deley
Journal: Journal of Clinical Oncology (2007)

9543 Background: Temozolomide has been shown moderately effective in pediatric high-grade glioma (HGG). By decreasing the activity of MGMT, principal mechanism of resistance to temozolomide, cisplatin may increase the activity of this alkylating agent. Methods: Patients aged 4 to 21y with HGG outside the brainstem were treated at diagnosis or at relapse every 28 days with a combination of cisplatin 80 mg/m 2 intravenously on day-1 and temozolomide 200 mg/m 2 orally on days 2–6, according to the pediatric phase I recommendations. Patients treated at diagnosis had to proceed to involved field radiotherapy after the chemotherapy window. According to initial response, patients were offered additional courses, up to seven. We considered that this combination would be of interest if the response rate was superior or equal to 20%, using a two-stage Simon design in 3 cohorts: evaluable non measurable (infiltrative) at diagnosis (cohort A1); measurable disease (nodular) at diagnosis (A2); recurrent disease (B). The primary endpoint was complete or partial response after two courses, confirmed by central review. Up to 29 evaluable pts were to be entered in each cohort. If fewer than 4/29 responses were observed, it would be concluded that the combination is ineffective. Results: 56 pts were entered from 10/2003 through 07/2006 in 25 centers. One was excluded after central pathology review and 3 due to insufficient radiology work-out. 42 had grade III and 13 grade IV gliomas, including 21 tumors with oligodendroglial features. No response was observed in the first 11 pts in cohort A1 and in the first 12 pts in cohort B. Two partial and 4 minor responses were confirmed in 29 pts of cohort A2 leading to a 7% response rate (95% CI, 1–23%). Median time to progression was 1.7, 7.1 and 6.9 months in cohorts A1, A2 and B, respectively. Toxicity was manageable except in pts with large infiltrative lesions who did not tolerate hydration. Conclusion: CISTEM combination has insufficient efficacy in pediatric compared to adult HGG despite efficient down-regulation of MGMT activity. To overcome resistance to temozolomide in children and adolescents, one may need to target other known resistance mechanisms such as mismatch-repair deficiency. [Table: see text]
DFMO upregulates transcription and translation of thrombospondin-1 (TSP-1) in vitro and increases steady state TSP-1 mRNA and protein levels in vivo in MDA-MB-435 breast cancer cells
Authors: Andrea Manni, Xin Hu, Sharlene Washington, Michael F. Verderame, Terry Rager
Journal: Cancer Research (2006)

1681  We have previously reported that alpha-difluoromethylornithine (DFMO) blocks metastasis and invasion of MDA-MB-435 breast cancer cells by activation of the MAPK pathway. Thrombospondin-1 (TSP-1) has been implicated in the suppression of metastasis in several systems; DFMO induces TSP-1 in MDA-MB-435 cells in a MAPK-dependent manner. Our present experiments were designed to investigate the regulation of TSP-1 by DFMO both in vitro and in vivo. Using an 35S-methionine pulse-chase assay in vitro we found that DFMO administration to MDA-MB 435 cells increased the TSP-1 protein synthesis rate by approximately 6-fold, although our data also show that DFMO reduced the half-life of TSP-1 modestly from 35 to 28 minutes. Using quantitative real time RT-PCR we found DFMO increased TSP-1 mRNA 2-fold. Using a TSP-1 promoter reporter assay we found that the relative luciferase activity of DFMO-treated cells is 1.5 times that of untreated cells. Using methylation specific PCR we found DFMO did not affect the degree of methylation of the TSP-1 promoter, suggesting this is not the mechanism responsible for increased transcription. The modest effect of DFMO on transcription compared to the robust induction of protein synthesis raises the possibility that a significant component of the DFMO effect may be at the translational level. The effect of DFMO on half life may reflect a change in secretion rate. In vivo we have repeatedly observed that DFMO administration to nude mice carrying human breast cancer cell MDA-MB-435 xenografts reduces the development of lung metastases by 90%. To determine if TSP-1 might play a role in vivo, we measured TSP-1 expression in these tumors. We observed that the TSP-1 mRNA in MDA-MB-435 xenografts was increased by DFMO administration, and the TSP-1 protein level was increased 2-fold. Overall, our results show that DFMO induces increased mRNA and translation in vitro, and increased mRNA and steady state protein in vivo. We are currently using siRNA to determine if TSP-1 is required for the DFMO-induced block to invasion and metastasis.
Primary results from TAIL, a global single-arm safety study of atezolizumab (atezo) monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer (NSCLC)
Authors: A. Ardizzoni, S. Azevedo, B. Rubio Viquiera, D. Rodriguez Abreu, J. Alatorre-Alexander, H.J. Smit, J. Yu, K. Syrigos, H. Patel, J. Tolson, A. Cardona, P. Perez Moreno, T. Newsom-Davis
Journal: Annals of Oncology (2019)
The role of EGFR inhibitor (EGFRi) in immune cell infiltration and CD8+ T-cell activation in EGFR mutant lung cancer
Authors: F. Li, G. Lizee, P. Hwu, X. Du, L. Deng, A. Talukder, A. Katailiha, Q. Zou, J. Roszik, D. Hawke, K. Jackson, S. Bradley, Y. Wang, R. Ataullakhanov, A. Bagaev, N. Kotlov, V. Svekolkin, N. Miheecheva, F. Frenkel, H. Sonnemann
Journal: Annals of Oncology (2019)
Novel fusion genes identified from matched primary and recurrent breast cancers by RNA-sequencing
Authors: S. Choi, J. Kim, I.Y. Chung, W.G. Jo, K.W. Yun, H.J. Park, S.B. Lee, H.J. Kim, B.S. Ko, J.W. Lee, B.H. Son, S.H. Ahn
Journal: Annals of Oncology (2019)
NY-ESO-1 and LAGE1A: An emerging target for cell therapies in solid tumours
Authors: I. Eleftheriadou, S. Brett, A. Domogala, L. Patasic, M.A. Kijewska, K. Soor, M. Georgouli, J. Dopierala, P. Fisher, J. Jing, J. Euesden, K.R. Auger, R. Roberts, S. O’Sullivan, L. Castelletti, M. Damm, D. Pankov, L.A. Johnson, A. Shalabi, C. Britten
Journal: Annals of Oncology (2019)
Clinical &amp; nutritional determinants of quality of life in patients with incurable cancer
Authors: L.E. Daly, E.S. Sullivan, R. Dolan, É B Ní Bhuachalla, S.J. Cushen, M. Fallon, C. Simmons, D.C. McMillan, B. Laird, A.M. Ryan, D.G. Power
Journal: Annals of Oncology (2019)
Clinicopathological and molecular criteria assessment for the screening of hypermutated proficient mismatch repair (pMMR) colorectal cancers (CRC) with exonucleasic domain POLE (edPOLE) mutations (mt)
Authors: BJ-C Rousseau, J. Cohen, J. Calderaro, A. Dupuy, R. Bourgoin, C. Tournigand, I. Baumgaertner, S. Ropert, A. Thirot Bidault, C. Klotz, C. Le Foll, H. Boussion, L.A. Diaz, M. Ollier, A. Pujals
Journal: Annals of Oncology (2019)
PULSE: A single arm trial assessing the activity and safety of avelumab immunotherapy maintenance among patients with locally advanced or metastatic squamous cell penile carcinoma (mSCPC)
Authors: N. Gassian, G. Mouillet, D. Vernerey, O. Manseur, A. Frontczak, A. Meurisse, D. Berthod, E. Robert, F. Calcagno, A. Thiery-Vuillemin
Journal: Annals of Oncology (2019)
A phase II study of pembrolizumab in combination with doxorubicin in advanced, recurrent or metastatic endometrial cancer
Authors: A. Oaknin, M J Rubio Perez, L Fariñas Madrid, A. Redondo, A Yubero Esteban, M Gil Martín, A González Martín, I. Romero, J. Garcia-Donas, R. Serrano, A Gallego Martínez, M Ocariz Diez, M L Sanchez Lorenzo, M D Fenor De La Maza Lopez Olmedo, V Rodriguez Freixinos, J M Piulats Rodriguez
Journal: Annals of Oncology (2019)
Treatment of Pityriasis Rubra Pilaris With Guselkumab
Authors: Anna Caroline Pilz, Peter Seiringer, Tilo Biedermann, Kilian Eyerich
Journal: JAMA Dermatology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)
Authors: D. Rischin, A.M. Lim, C.D. Schmults, N.I. Khushalani, B.G. Hughes, D. Schadendorf, L.A. Dunn, A.L.S. Chang, A. Hauschild, C. Ulrich, T. Eigentler, M.R. Migden, A.C. Pavlick, J. Geiger, E. Stankevich, S. Li, I. Lowy, M.G. Fury, A. Guminski
Journal: Annals of Oncology (2019)
Multicenter phase II trial of axitinib monotherapy for advanced biliary tract cancer refractory to gemcitabine-based chemotherapy
Authors: N. Okano, M. Ueno, C. Morizane, T. Yamanaka, H. Ojima, M. Ozaka, M. Sasaki, N. Takahara, S. Kobayashi, M. Morimoto, H. Hosoi, Y. Nakai, M. Ikeda, S. Maeno, F. Nagashima, T. Okusaka, J. Furuse
Journal: Annals of Oncology (2019)
Prognostic factors for efficacy of Ipilimumab used after anti-PD1 and/or BRAF+MEK inhibitors in melanoma patients: An Italian melanoma intergroup study
Authors: R. Marconcini, A. Nuzzo, S. Manacorda, F. de rosa, P. Fava, C. Astrua, L.A. Di Guardo, A. Raimondi, S.L. Stucci, A. Todisco, A. Cortellini, M. Bersanelli, O. Nigro, M. Palla, G. Palmieri, A. Falcone
Journal: Annals of Oncology (2019)
Matched whole-genome sequencing and whole-exome sequencing with circulating tumor DNA (ctDNA) analysis are complementary modalities in clinical practice
Authors: R. Imperial, M. Nazer, S.G. Pappas, T. Kuzel, B. El-Rayes, T. Pluard, M. Levy, J. Subramanian, A. Masood
Journal: Annals of Oncology (2019)